Disclosure of voting rights for Chairman of the Board
24 mai 2022 04h44 HE
|
PCI Biotech Holding ASA
Oslo, 24 May 2022. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...
PCI Biotech interim first quarter 2022 results
11 mai 2022 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 11 May 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2022 results. Please find enclosed the report and presentation. ...
PCI Biotech to present at TIDES USA 2022
09 mai 2022 02h45 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 9 May 2022 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced a...
PCI Biotech: Invitation to Q1 2022 results presentation
04 mai 2022 09h10 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 4 May 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q1 2022 interim report on Wednesday 11 May 2022, 08:30am – 09:30am CEST (local time). The...
Notice of Annual General Meeting 2022
04 mai 2022 05h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway 4 May 2022 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 25 May 2022 at 10:00am (CEST). The...
PCI Biotech Holding ASA publishes the Annual Report 2021
28 avr. 2022 04h59 HE
|
PCI Biotech Holding ASA
Oslo, Norway, April 28, 2022The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2021 and the report is attached, in addition to the report according to the European Single...
PCI Biotech: CEO resigns to assume new position
28 mars 2022 08h21 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 28 March 2022 – PCI Biotech (OSE: PCIB) announces today that CEO, Dr Per Walday has resigned to assume a new position. Dr Walday has a notice period of six months, and he will step down...
PCI Biotech fourth quarter and preliminary full year 2021 results
18 févr. 2022 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 18 February 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full-year 2021 results. Please find enclosed the...
PCI Biotech: Invitation to Q4 2021 result presentation
14 févr. 2022 06h50 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 14 February 2022 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q4 and preliminary full-year 2021 results on Friday 18 February 2022 at Oslo Cancer Cluster...
PCI Biotech: Update on the RELEASE trial
24 janv. 2022 15h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 24 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company has decided to stop the RELEASE study and focus their drug...